2024
Ginkgo biloba for Tardive Dyskinesia and Plasma MnSOD Activity: Association with MnSOD Ala-9Val Variant: A Randomized, Double-blind Trial
Wang D, Tian Y, Chen J, Zhu R, Li J, Zhou H, Chen D, Wang L, Kosten T, Zhang X. Ginkgo biloba for Tardive Dyskinesia and Plasma MnSOD Activity: Association with MnSOD Ala-9Val Variant: A Randomized, Double-blind Trial. Current Neuropharmacology 2024, 22: 2443-2452. PMID: 38919004, PMCID: PMC11451319, DOI: 10.2174/1570159x22666240530095721.Peer-Reviewed Original ResearchAbnormal Involuntary Movement ScaleMnSOD Ala-9Val polymorphismTardive dyskinesiaTD patientsTD symptomsAla-9Val polymorphismPathophysiology of tardive dyskinesiaNon-TDHealthy controlsNon-TD patientsSeverity of TDMovement ScaleAla alleleDouble-blind clinical trialIncreased MnSOD activityMnSOD activityWeeks of treatmentVal/Val genotypeTreatment responseDyskinesiaGinkgo biloba extractEGb761 groupManganese superoxide dismutaseSymptomsClinical trials
2020
Pharmacologic Treatment of Tardive Dyskinesia: A Meta-Analysis and Systematic Review.
Artukoglu BB, Li F, Szejko N, Bloch MH. Pharmacologic Treatment of Tardive Dyskinesia: A Meta-Analysis and Systematic Review. The Journal Of Clinical Psychiatry 2020, 81 PMID: 32459404, DOI: 10.4088/jcp.19r12798.Peer-Reviewed Original ResearchConceptsTreatment of TDGreater score reductionPlacebo-controlled trialTardive dyskinesiaVitamin EPharmacologic treatmentTD symptomsScore reductionSystematic reviewPublication biasVesicular monoamine transporter 2 (VMAT2) inhibitorTardive dyskinesia treatmentVitamin E studiesTransporter 2 inhibitorsCalcium channel blockersDuration of treatmentTardive dyskinesia symptomsGreater reductionFixed-effects modelMedication classesHead trialsDyskinesia symptomsPrimary outcomePharmacologic agentsVMAT2 inhibitors
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply